Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development

Background Although paediatric high grade gliomas resemble their adult counterparts in many ways, there appear to be distinct clinical and biological differences. One important factor hampering the development of new targeted therapies is the relative lack of cell lines derived from childhood glioma patients, as it is unclear whether the well-established adult lines commonly used are representative of the underlying molecular genetics of childhood tumours. We have carried out a detailed molecular and phenotypic characterisation of a series of paediatric high grade glioma cell lines in comparison to routinely used adult lines. Principal Findings All lines proliferate as adherent monolayers and express glial markers. Copy number profiling revealed complex genomes including amplification and deletions of genes known to be pivotal in core glioblastoma signalling pathways. Expression profiling identified 93 differentially expressed genes which were able to distinguish between the adult and paediatric high grade cell lines, including a number of kinases and co-ordinated sets of genes associated with DNA integrity and the immune response. Significance These data demonstrate that glioma cell lines derived from paediatric patients show key molecular differences to those from adults, some of which are well known, whilst others may provide novel targets for evaluation in primary tumours. We thus provide the rationale and demonstrate the practicability of using paediatric glioma cell lines for preclinical and mechanistic studies.

[1]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[2]  P. Burger,et al.  Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma , 2008, Journal of neuropathology and experimental neurology.

[3]  J. Schouten,et al.  Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences , 2005, Nucleic acids research.

[4]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[5]  W. Poon,et al.  Genetic alterations in pediatric high-grade astrocytomas. , 1999, Human pathology.

[6]  Erwin G. Van Meir,et al.  Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. , 2004, The American journal of pathology.

[7]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[8]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[9]  P. Wesseling,et al.  MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas , 2007, Laboratory Investigation.

[10]  K. Wong,et al.  Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. , 2006, Cancer research.

[11]  A Leviton,et al.  Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors , 2000, Cancer.

[12]  P. Liberski,et al.  Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Ellenbogen,et al.  O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines , 2005, Clinical Cancer Research.

[14]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[15]  Emily C. Brantley,et al.  Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas , 2008, Molecular Cancer Research.

[16]  D. Gisselsson,et al.  Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.

[17]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[18]  A. Ashworth,et al.  Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.

[19]  S. Zacharoulis,et al.  Pediatric CNS tumors: current treatment and future directions , 2007, Expert review of neurotherapeutics.

[20]  M. Massimino,et al.  Phase II trial of temozolomide in children with recurrent high-grade glioma , 2006, Journal of Neuro-Oncology.

[21]  M. Weller,et al.  Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. , 2006, Current pharmaceutical design.

[22]  Mitsutoshi Nakamura,et al.  Molecular pathogenesis of pediatric astrocytic tumors. , 2007, Neuro-oncology.

[23]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[24]  K. Geiger,et al.  Cytogenetic and molecular cytogenetic analyses in diffuse astrocytomas. , 2004, Cancer genetics and cytogenetics.

[25]  H. Friedman,et al.  Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors , 2007, Cancer.

[26]  T. Zhou,et al.  O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[28]  G. Barger,et al.  In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.

[29]  T. Merchant,et al.  Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children , 2006, Journal of Neuro-Oncology.

[30]  H. Wheeler,et al.  Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma , 2008, Journal of Clinical Neuroscience.

[31]  R. Eils,et al.  An optimized, fully automated system for fast and accurate identification of chromosomal rearrangements by multiplex-FISH (M-FISH) , 1998, Cytogenetic and Genome Research.

[32]  N. Potter,et al.  Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. , 2008, Neoplasia.

[33]  D. Ellison,et al.  Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Bjerkvig,et al.  DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? , 2008, Cancer treatment reviews.

[35]  Karin Reed,et al.  Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. , 2002, Biochemical pharmacology.

[36]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Allebeck,et al.  Short communication , 1994, Agroforestry Systems.

[38]  H. Jürgens,et al.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.

[39]  A. Reddy Advances in biology and treatment of childhood brain tumors , 2001, Current neurology and neuroscience reports.

[40]  A. Look,et al.  Oncogene amplification in pediatric brain tumors. , 1990, Cancer research.

[41]  G. Vassal,et al.  Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. , 2009, Cancer research.